Maurits S. Boon, MD, who contributed to Nyxoah’s DREAM US trial for the Genio system, brings surgical and academic expertise in hypoglossal nerve stimulation.

Summary: Nyxoah SA has appointed Maurits S. Boon, MD, who is recognized for his work in hypoglossal nerve stimulation therapy to treat obstructive sleep apnea, as chief medical officer. Boon, from Thomas Jefferson University, contributed to Nyxoah’s DREAM US trial, which demonstrated a 70.8% reduction in the apnea-hypopnea index with the Genio system. His expertise will support Nyxoah’s US Food and Drug Administration approval efforts and its mission to improve obstructive sleep apnea patient care.

Key Takeaways: 

  • Maurits S. Boon, MD has been appointed as the chief medical officer at Nyxoah SA, where he will leverage his expertise in hypoglossal nerve stimulation to enhance treatments for obstructive sleep apnea.
  • Boon was a contributor to Nyxoah’s DREAM US pivotal study, which reported a 70.8% median reduction in the apnea-hypopnea index among participants using the Genio system.
  • Boon is dual board-certified in otolaryngology – head and neck surgery, as well as sleep medicine, and he remains a part-time professor and vice chairman of education at Thomas Jefferson University. He is internationally recognized for his work in sleep surgery, particularly hypoglossal nerve stimulation procedures.

Nyxoah SA, maker of the CE-marked Genio neurostimulator for the treatment of obstructive sleep apnea, has appointed Maurits S. Boon, MD, as chief medical officer.

Boon joins Nyxoah from the Thomas Jefferson University, where he will continue part-time as a professor and vice chairman of education. He is dual board-certified in otolaryngology – head and neck surgery, as well as sleep medicine. 

Boon is one of two sleep surgeons with Jefferson Health to pioneer the use of hypoglossal nerve stimulation therapy and is internationally recognized as one of the most experienced surgeons performing hypoglossal nerve stimulation procedures, according to a release from Nyxoah. He has lectured worldwide on obstructive sleep apnea, has numerous publications, and is co-editor of the first book on hypoglossal nerve stimulation.

DREAM US Study Success Supports New CMO’s Vision for Market Expansion

Nyxoah recently announced 12-month results of its DREAM US pivotal study—which Boon participated in—designed to support the marketing authorization of the Genio hypoglossal nerve stimulation system for obstructive sleep apnea in the United States. Subjects demonstrated a median 12-month apnea-hypopnea index (AHI) reduction of 70.8%, with similar AHI improvements in supine and non-supine sleeping positions.

“As an academic physician who has dedicated my professional career to the care of patients with sleep-disordered breathing, I was privileged to participate in the DREAM US pivotal trial. I was initially impressed by the results I saw in my patients and then equally impressed by the data that were recently reported. As such, I am honored to have been offered a position to join Nyxoah at such an exciting time. 

“Bilateral hypoglossal nerve stimulation with Genio has tremendous potential, and I am thrilled to work with their talented team to make a meaningful impact on the lives of patients with obstructive sleep apnea,” says Boon in a release.

Nyxoah is now finalizing the fourth and final module submission in the premarket approval application to submit for US Food and Drug Administration approval. 

“I could not be more excited to have Dr Boon join Nyxoah,” says Olivier Taelman, chief executive officer of Nyxoah in a release. “He is one of the pioneers in hypoglossal nerve stimulation, and his decision to become Nyxoah’s chief medical officer reflects Genio’s ability to improve the lives of OSA patients. Dr Boon will play a critical role as we prepare to enter the US market and achieve our mission of making sleep simple again.”

Photo caption: Maurits S. Boon, MD

Photo credit: Nyxoah SA